AR035069A1 - Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento - Google Patents

Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento

Info

Publication number: AR035069A1
Authority: AR; Argentina
Prior art keywords: alkyl; ring; heteroaryl; independently selected; cycloalkyl
Prior art date: 2000-10-26

Application number

ARP010104977A

Other languages

English (en)

Spanish (es)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-26

Filing date

2001-10-24

Publication date

2004-04-14

2001-10-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-04-14 Publication of AR035069A1 publication Critical patent/AR035069A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
230000002401 inhibitory effect Effects 0.000 title 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
125000001072 heteroaryl group Chemical group 0.000 abstract 10
125000000623 heterocyclic group Chemical group 0.000 abstract 10
125000001424 substituent group Chemical group 0.000 abstract 9
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 8
125000000041 C6-C10 aryl group Chemical group 0.000 abstract 8
125000000217 alkyl group Chemical group 0.000 abstract 6
229910052757 nitrogen Inorganic materials 0.000 abstract 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
229920001774 Perfluoroether Polymers 0.000 abstract 4
125000004432 carbon atom Chemical group C* 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000005010 perfluoroalkyl group Chemical group 0.000 abstract 4
125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 3
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 3
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 3
229910052799 carbon Inorganic materials 0.000 abstract 3
125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
102000005741 Metalloproteases Human genes 0.000 abstract 2
108010006035 Metalloproteases Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
102000003843 Metalloendopeptidases Human genes 0.000 abstract 1
108090000131 Metalloendopeptidases Proteins 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000002837 carbocyclic group Chemical group 0.000 abstract 1
150000001721 carbon Chemical group 0.000 abstract 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
210000002808 connective tissue Anatomy 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
230000009933 reproductive health Effects 0.000 abstract 1
230000000241 respiratory effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pregnancy & Childbirth (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)

ARP010104977A 2000-10-26 2001-10-24 Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento AR035069A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24338900P	2000-10-26	2000-10-26

Publications (1)

Publication Number	Publication Date
AR035069A1 true AR035069A1 (es)	2004-04-14

Family

ID=22918584

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP010104977A AR035069A1 (es)	2000-10-26	2001-10-24	Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento

Country Status (32)

Country	Link
EP (1)	EP1332146A2 (cs)
JP (1)	JP2004518635A (cs)
KR (1)	KR20040004412A (cs)
CN (1)	CN1501937A (cs)
AP (1)	AP2001002318A0 (cs)
AR (1)	AR035069A1 (cs)
AU (1)	AU2002210813A1 (cs)
BG (1)	BG107653A (cs)
BR (1)	BR0114913A (cs)
CA (1)	CA2425283A1 (cs)
CZ (1)	CZ20031083A3 (cs)
EA (1)	EA005762B1 (cs)
EC (1)	ECSP034567A (cs)
EE (1)	EE200300196A (cs)
GT (1)	GT200100213A (cs)
HN (1)	HN2001000244A (cs)
HR (1)	HRP20030332A2 (cs)
HU (1)	HUP0301577A3 (cs)
IL (1)	IL154948A0 (cs)
IS (1)	IS6762A (cs)
MA (1)	MA26957A1 (cs)
MX (1)	MXPA03003735A (cs)
NO (1)	NO20031853L (cs)
OA (1)	OA12529A (cs)
PA (1)	PA8531401A1 (cs)
PE (1)	PE20020589A1 (cs)
PL (1)	PL366201A1 (cs)
SK (1)	SK4972003A3 (cs)
SV (1)	SV2003000705A (cs)
TN (1)	TNSN01149A1 (cs)
WO (1)	WO2002034753A2 (cs)
ZA (1)	ZA200302190B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA03005870A (es)	2001-02-14	2005-02-14	Warner Lambert Co	Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
JP2004518723A (ja)	2001-02-14	2004-06-24	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	ピリミジンマトリックスメタロプロテイナーゼ阻害剤
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
MXPA04002537A (es)	2001-10-12	2004-05-31	Warner Lambert Co	Alquinos como inhibidores de metaloproteinasa de matriz.
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
AU2003228701A1 (en) *	2002-04-25	2003-11-10	Bristol-Myers Squibb Company	Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
AU2003216660A1 (en) *	2002-04-26	2003-11-10	Pfizer Products Inc.	N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
JP2005527598A (ja) *	2002-04-26	2005-09-15	ファイザー・プロダクツ・インク	トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤
WO2004014375A2 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014378A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249477A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
CA2497658A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
MXPA05001603A (es) *	2002-08-13	2005-04-25	Warner Lambert Co	Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
MXPA05001783A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
US7208490B2 (en)	2002-10-07	2007-04-24	Pharmacia & Upjohn Company Llc	Tricyclic tetrahydroquinoline antibacterial agents
GB0223249D0 (en) *	2002-10-08	2002-11-13	Amersham Plc	Improved imaging agents
WO2004084903A1 (en) *	2003-03-27	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) *	2003-03-28	2004-10-07	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment of chronic wounds
FR2858232B1 (fr) *	2003-07-29	2006-03-03	Pierre Potier	Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
WO2005097133A1 (en) *	2004-04-01	2005-10-20	F. Hoffmann-La Roche Ag	Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
DOP2006000268A (es)	2005-12-22	2007-07-31	Pfizer Prod Inc	Agentes antibacterianos
US8153166B2 (en) *	2006-06-08	2012-04-10	Chih-Hsiung Lin	Composition for prophylaxis or treatment of urinary system infection and method thereof
CN102285934B (zh) *	2009-01-08	2013-08-14	四川大学	螺环二烯酮衍生物及其制备方法和用途
MY178583A (en) *	2012-12-10	2020-10-16	Chugai Pharmaceutical Co Ltd	Hydantoin derivative
KR101594506B1 (ko) *	2014-03-20	2016-02-17	한국화학연구원	골 관련 질환 치료용 조성물
MX371090B (es)	2014-06-09	2020-01-16	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica que contiene derivado de hidantoina.
AU2019387367A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Diarylhydantoin compounds and methods of use thereof
CN110092790B (zh) *	2019-06-11	2020-07-24	东北农业大学	一种生物碱类化合物及其制备方法和应用
TW202606695A (zh) *	2024-04-24	2026-02-16	美商塞普特納公司	含有取代或修飾的二胺基亞甲基嘧啶—２，４，６—三酮的副甲狀腺素１受體和腸促胰島素受體的激動劑
WO2025226892A1 (en) *	2024-04-24	2025-10-30	Septerna, Inc.	Spirocycle-containing diaminomethylene pyrimidine-2,4,6-trione agonists of parathyroid hormone 1 and incretin receptors
WO2026107328A1 (en) *	2024-11-15	2026-05-21	Septerna, Inc.	Agonists of parathyroid hormone 1 and incretin receptors
CN121648128B (zh) *	2026-02-03	2026-06-30	华中科技大学同济医学院附属同济医院	特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3714093A (en) *	1970-05-19	1973-01-30	American Home Prod	Spiro [heterocycloalkyl-2'(1'h)-quinazoline]-4'(3'h)-ones
EP0989982B1 (en) *	1997-06-21	2005-08-17	Roche Diagnostics GmbH	Barbituric acid derivatives with antimetastatic and antitumor activity
US6265578B1 (en) *	1999-02-12	2001-07-24	Hoffmann-La Roche Inc.	Pyrimidine-2,4,6-triones
HN2000000137A (es) *	1999-08-12	2001-02-02	Pfizer Prod Inc	Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas

2001
- 2001-10-23 CZ CZ20031083A patent/CZ20031083A3/cs unknown
- 2001-10-23 PL PL01366201A patent/PL366201A1/xx not_active Application Discontinuation
- 2001-10-23 BR BR0114913-0A patent/BR0114913A/pt not_active IP Right Cessation
- 2001-10-23 HU HU0301577A patent/HUP0301577A3/hu unknown
- 2001-10-23 IL IL15494801A patent/IL154948A0/xx unknown
- 2001-10-23 AP APAP/P/2001/002318A patent/AP2001002318A0/en unknown
- 2001-10-23 KR KR10-2003-7005753A patent/KR20040004412A/ko not_active Ceased
- 2001-10-23 AU AU2002210813A patent/AU2002210813A1/en not_active Abandoned
- 2001-10-23 EE EEP200300196A patent/EE200300196A/xx unknown
- 2001-10-23 HR HR20030332A patent/HRP20030332A2/hr not_active Application Discontinuation
- 2001-10-23 SK SK497-2003A patent/SK4972003A3/sk unknown
- 2001-10-23 CA CA002425283A patent/CA2425283A1/en not_active Abandoned
- 2001-10-23 EP EP01978721A patent/EP1332146A2/en not_active Withdrawn
- 2001-10-23 CN CNA018179231A patent/CN1501937A/zh active Pending
- 2001-10-23 EA EA200300306A patent/EA005762B1/ru not_active IP Right Cessation
- 2001-10-23 JP JP2002537743A patent/JP2004518635A/ja not_active Withdrawn
- 2001-10-23 MX MXPA03003735A patent/MXPA03003735A/es unknown
- 2001-10-23 WO PCT/IB2001/001986 patent/WO2002034753A2/en not_active Ceased
- 2001-10-23 OA OA1200300123A patent/OA12529A/en unknown
- 2001-10-24 HN HN2001000244A patent/HN2001000244A/es unknown
- 2001-10-24 AR ARP010104977A patent/AR035069A1/es unknown
- 2001-10-25 SV SV2001000705A patent/SV2003000705A/es unknown
- 2001-10-25 PE PE2001001060A patent/PE20020589A1/es not_active Application Discontinuation
- 2001-10-25 GT GT200100213A patent/GT200100213A/es unknown
- 2001-10-25 TN TNTNSN01149A patent/TNSN01149A1/fr unknown
- 2001-10-26 PA PA20018531401A patent/PA8531401A1/es unknown
2003
- 2003-03-19 ZA ZA200302190A patent/ZA200302190B/en unknown
- 2003-03-20 BG BG107653A patent/BG107653A/bg unknown
- 2003-03-27 IS IS6762A patent/IS6762A/is unknown
- 2003-04-22 MA MA27117A patent/MA26957A1/fr unknown
- 2003-04-24 NO NO20031853A patent/NO20031853L/no not_active Application Discontinuation
- 2003-04-25 EC EC2003004567A patent/ECSP034567A/es unknown

Also Published As

Publication number	Publication date
CN1501937A (zh)	2004-06-02
NO20031853L (no)	2003-06-23
PL366201A1 (en)	2005-01-24
MXPA03003735A (es)	2003-07-28
AP2001002318A0 (en)	2001-12-31
SV2003000705A (es)	2003-01-13
TNSN01149A1 (fr)	2005-11-10
ZA200302190B (en)	2004-04-28
GT200100213A (es)	2002-07-03
KR20040004412A (ko)	2004-01-13
IS6762A (is)	2003-03-27
BG107653A (bg)	2003-12-31
HN2001000244A (es)	2003-11-07
JP2004518635A (ja)	2004-06-24
SK4972003A3 (en)	2004-05-04
EP1332146A2 (en)	2003-08-06
WO2002034753A2 (en)	2002-05-02
IL154948A0 (en)	2003-10-31
HUP0301577A3 (en)	2006-02-28
CA2425283A1 (en)	2002-05-02
HRP20030332A2 (en)	2003-06-30
WO2002034753A3 (en)	2002-08-15
EE200300196A (et)	2003-10-15
AU2002210813A1 (en)	2002-05-06
MA26957A1 (fr)	2004-12-20
PE20020589A1 (es)	2002-07-06
ECSP034567A (es)	2003-06-25
NO20031853D0 (no)	2003-04-24
HUP0301577A2 (hu)	2003-11-28
OA12529A (en)	2006-06-02
EA005762B1 (ru)	2005-06-30
PA8531401A1 (es)	2003-06-30
EA200300306A1 (ru)	2003-08-28
BR0114913A (pt)	2003-07-01
CZ20031083A3 (cs)	2004-03-17

Legal Events

Date	Code	Title	Description
2007-06-06	FB	Suspension of granting procedure

Publication	Publication Date	Title
CY1110969T1 (el)	2015-06-11	5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
CO5261625A1 (es)	2003-03-31	Novedoso derivados fenilheteroalquilamina, procesos para su prepraracion, coposiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
SE9702799D0 (sv)	1997-07-25	New compounds
BRPI0410979A (pt)	2006-07-04	composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
ATE194987T1 (de)	2000-08-15	Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
ECSP045469A (es)	2005-01-28	El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
DE602004015277D1 (de)	2008-09-04	Substituierte-1-phthalazinamine als vr-1-antagonisten
AR040928A1 (es)	2005-04-27	Compuestos de acidos sulfona-hidroxamicos aromaticos, composiciones farmaceuticas y su uso en la preparacion de medicamentos utiles como inhibidores de proteasas
NO923200D0 (no)	1992-08-14	Piperidin-derivater
UY28688A1 (es)	2005-07-29	Derivados de amida
PT871626E (pt)	2002-04-29	Triazolonas utilizadas como inibidores de sintese da apoliproteina b
DK1412332T3 (da)	2005-05-30	Quinolinderivater og anvendelse deraf som antitumormidler
AR038094A1 (es)	2004-12-29	Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica
FI923662A0 (fi)	1992-08-14	Terapeutiska medel.
DE60103034D1 (de)	2004-06-03	Neue phenylheteroalkylamin-derivate
ATE320797T1 (de)	2006-04-15	Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DK1174131T3 (da)	2007-02-05	Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
GB0030729D0 (en)	2001-01-31	Substituted-4-Quinolones
AR035219A1 (es)	2004-05-05	Compuesto de 1, 2, 3, 4, 4a, 5, 6, 7, 8, 8 a-decahidroisoquinolina, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica y procedimiento para preparar dicho compuesto
DE60103035D1 (de)	2004-06-03	Neue verwendung von phenylheteroalkylamin-derivaten
DE60005525D1 (de)	2003-10-30	2-aminotetraline zur behandlung von glaukom
PT1144417E (pt)	2002-12-31	4', 5'-di-hidropsolarenos substituidos na posicao 4' e suas utilizacoes terapeuticas
TH66556A (th)	2005-01-21	สารยับยั้งเมททัลโลโพรทีเนส สไพโร-ไพริมิดีน-2,4,6-ไตรโอน
RU98114985A (ru)	2000-06-20	Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы
DE60000556D1 (de)	2002-11-14	Tetrazolylalkyl-Indolderivate als entzündungshemmende und analgetische Mittel